Cover Image
Market Research Report
Product code 
1058160

Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Published: | IMARC Services Private Limited | 147 Pages | Delivery time: 2-3 business days

Price

Back to Top
Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
Published: February 12, 2022
IMARC Services Private Limited
Content info: 147 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global orphan drugs market reached a value of US$ 168.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 342.4 Billion by 2027, exhibiting a CAGR of 12.3% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

  • Biological
  • Non-Biological

Breakup by Disease Type:

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Breakup by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Breakup by Top Selling Drugs:

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report:

  • How has the global orphan drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global orphan drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the phase?
  • What is the breakup of the market based on the top selling drugs?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global orphan drugs market and who are the key players?
  • What is the degree of competition in the industry?
Product Code: SR0222A15_Report

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orphan Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Phase

  • 8.1 Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

  • 9.1 Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7 Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8 Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9 Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10 Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Alexion Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Amgen Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Biogen Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Bristol Myers Squibb Company
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 Jazz Pharmaceuticals Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Sanofi S.A.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Takeda Pharmaceutical Company Limited
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis
    • 16.3.14 Teva Pharmaceutical Industries Ltd
      • 16.3.14.1 Company Overview
      • 16.3.14.2 Product Portfolio
      • 16.3.14.3 Financials
      • 16.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2021
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2021
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2021
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2021
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2021
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2021
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2022-2027
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2022-2027
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2022-2027
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2022-2027
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players